Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aim: Proton pump inhibitors (PPIs) may increase the risk of COVID-19 among non-vaccinated subjects via various mechanisms, including gut dysbiosis. We aimed to investigate whether PPIs also affect the clinical outcomes of COVID-19 among vaccine recipients.
Methods: This was a territory-wide cohort study of 3 272 286 vaccine recipients (aged ≥ 18 years) of ≥ 2 doses of either BNT162b2 or CoronaVac. Exclusion criteria included prior gastrointestinal surgery, immunocompromised status, and prior COVID-19. The primary outcome was COVID-19, and secondary outcomes included COVID-19-related hospitalization and severe infection (composite of intensive care unit admission, ventilatory support, and/or death). Covariates include age, sex, the Charlson Comorbidity Index, comorbidities, and concomitant medication use. Subjects were followed from index date (first dose of vaccination) until outcome occurrence, death, additional dose of vaccination, or March 31, 2022. Exposure was pre-vaccination PPI use (any prescription within 90 days before the index date). Propensity score (PS) matching and a Poisson regression model were used to estimate the adjusted incidence rate ratio (aIRR) of outcomes with PPI use.
Results: Among 439 154 PS-matched two-dose vaccine recipients (mean age: 65.3 years; male: 45.7%) with a median follow-up of 6.8 months (interquartile range: 2.6-7.9), PPI exposure was associated with a higher risk of COVID-19 (aIRR: 1.08; 95% confidence interval [95% CI]: 1.05-1.10), hospitalization (aIRR: 1.20; 95% CI: 1.08-1.33), and severe infection (aIRR: 1.57; 95% CI: 1.24-1.98). Among 188 360 PS-matched three-dose vaccine recipients (mean age: 62.5 years; male: 49.0%; median follow-up: 9.1 months [interquartile range: 8.0-10.9]), PPIs were associated with higher infection risk (aIRR: 1.11; 95% CI: 1.08-1.15) but not other outcomes.
Conclusions: Although PPI use was associated with a higher COVID-19 risk, severe infection was limited to two-dose but not three-dose vaccine recipients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jgh.16601 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transient increased risk of shingles post Shingrix vaccination: Self-controlled case series analysis.
Clin Infect Dis
September 2025
Epidemiology Informatics, Centre for Health Analytics, Melbourne Children's Campus, Parkville, Victoria, Australia.
Background: Following the introduction of a funded recombinant shingles (RZV, Shingrix®) vaccination program in ≥65 years in Australia, clinician reports of shingles presentations shortly after vaccination emerged. We investigated whether there was an increase in shingles risk immediately post RZV vaccination in South-eastern Australia.
Methods: Two independent datasets- a general practice dataset and a statewide linked dataset- were analysed separately using self-controlled case series analyses (SCCS) with 21-days post-vaccination as the risk window.
Structure-guided loop grafting improves expression and stability of influenza neuraminidase for vaccine development.
Elife
September 2025
Chinese Academy of Medical Science Oxford Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Influenza virus neuraminidase (NA) is a crucial target for protective antibodies, yet the development of recombinant NA protein as a vaccine has been held back by instability and variable expression. We have taken a pragmatic approach to improving expression and stability of NA by grafting antigenic surface loops from low-expressing NA proteins onto the scaffold of high-expressing counterparts. The resulting hybrid proteins retained the antigenic properties of the loop donor while benefiting from the high-yield expression, stability, and tetrameric structure of the loop recipient.
View Article and Find Full Text PDFPay-It-Forward 23-Valent Pneumococcal Polysaccharide Vaccination Among Older Adults: Protocol for a Randomized Controlled Trial.
JMIR Res Protoc
September 2025
Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health & Life Science Institute, Guangxi Medical University, Nanning, China.
Background: The 23-valent pneumococcal polysaccharide vaccine reduces the risk of pneumonia among adults by 38% to 46%. However, only a few older adults in resource-limited areas of China have received the pneumococcal vaccination. Pay-it-forward is a social innovation that offers participants free or subsidized health services and a community-engaged message, with an opportunity to donate to support subsequent recipients.
View Article and Find Full Text PDFImmunogenicity comparison of an -produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trial.
Lancet Reg Health West Pac
September 2025
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, China.
Background: Cecolin9, a second-generation 9-valent HPV vaccine derived from the WHO-prequalified Cecolin, has received marketing authorisation in China in May 2025. The non-inferiority of type-specific immune responses between Cecolin9 and Gardasil9 has been previously established at month 7 in Chinese women aged 18-26 years (NCT04782895). This study aimed to compare the plateau antibody levels between the two vaccines three years post the first dose.
View Article and Find Full Text PDFHepatitis E in the pediatric population: An overlooked disease but a genuine concern?
Clin Exp Hepatol
June 2025
Collegium Medicum, Jan Kochanowski University of Kielce, Poland.
Hepatitis E virus (HEV) is a significant yet underdiagnosed cause of acute and chronic hepatitis, particularly in pediatric populations. While HEV infection in children is often asymptomatic or mild, it can progress to severe outcomes in immunocompromised patients, such as organ transplant recipients or those undergoing chemotherapy. HEV genotypes 1 and 2 are predominantly responsible for waterborne outbreaks in endemic regions, whereas genotypes 3 and 4 are associated with zoonotic transmission in developed countries.
View Article and Find Full Text PDF